Exclusive license agreement
June 29, 2016
Solural Pharma ApS enters into an exclusive license agreement with Dyna Therapeutics Co., Ltd, Korea to develop and commercialize SOL-804 for treatment of metastatic castration resistant prostate cancer. SOL-804 is based on the proprietary Solural Lymphatic Targeting Technology.
Recent news
- Updated Manufacturing and Importation Authorisation February 13, 2018
- Solural Pharma gets a European patent August 9, 2017
- Ascelia Pharma AB acquires Oncoral Pharma ApS June 30, 2017
Contact us
- Energivej 42, DK 2750 Ballerup, Copenhagen, Denmark
- info@soluralpharma.com
- Find us on map